Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 7Tumor-Agnostic 3Other solid neoplasm 3Thoracic 2Gynecologic 2CNS 2Classical hematology 1

Conditions

Solid Tumors 1Advanced Solid Tumors 1Advance Solid Tumors 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × iniparib × Other solid neoplasm × Clear all
NCT01593228 2017-09-19

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Sanofi

Phase 3 Completed
37 enrolled
Other solid neoplasm

Solid Tumors

NCT01161836 2013-09-24

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Sanofi

Phase 1 Completed
7 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT01213381 2013-05-24

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advance Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡